🎉 M&A multiples are live!
Check it out!

Mesoblast Valuation Multiples

Discover revenue and EBITDA valuation multiples for Mesoblast and similar public comparables like Cynata Therapeutics, Aroa Biosurgery, and Orthocell.

Mesoblast Overview

About Mesoblast

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.


Founded

2004

HQ

Australia
Employees

73

Website

mesoblast.com

Financials

LTM Revenue $25.4M

LTM EBITDA -$71.7M

EV

$1.8B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Mesoblast Financials

Mesoblast has a last 12-month revenue of $25.4M and a last 12-month EBITDA of -$71.7M.

In the most recent fiscal year, Mesoblast achieved revenue of $3.7M and an EBITDA of -$39.7M.

Mesoblast expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Mesoblast valuation multiples based on analyst estimates

Mesoblast P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $4.7M $3.7M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$37.0M -$39.7M XXX XXX XXX
EBITDA Margin -781% -1064% XXX XXX XXX
Net Profit -$57.8M -$51.8M XXX XXX XXX
Net Margin -1218% -1387% XXX XXX XXX
Net Debt $23.1M $23.9M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Mesoblast Stock Performance

As of March 14, 2025, Mesoblast's stock price is AUD 2 (or $1).

Mesoblast has current market cap of AUD 2.6B (or $1.7B), and EV of AUD 2.8B (or $1.8B).

See Mesoblast trading valuation data

Mesoblast Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.8B $1.7B XXX XXX XXX XXX $-0.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Mesoblast Valuation Multiples

As of March 14, 2025, Mesoblast has market cap of $1.7B and EV of $1.8B.

Mesoblast's trades at 109.0x LTM EV/Revenue multiple, and -38.6x LTM EBITDA.

Analysts estimate Mesoblast's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Mesoblast and 10K+ public comps

Mesoblast Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.8B XXX XXX XXX
EV/Revenue 145.2x XXX XXX XXX
EV/EBITDA -42.1x XXX XXX XXX
P/E -26.0x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -35.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Mesoblast Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Mesoblast Valuation Multiples

Mesoblast's NTM/LTM revenue growth is 359%

Mesoblast's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.6M for the same period.

Over next 12 months, Mesoblast's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Mesoblast's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Mesoblast and other 10K+ public comps

Mesoblast Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -21% XXX XXX XXX XXX
EBITDA Margin -345% XXX XXX XXX XXX
EBITDA Growth 7% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 14% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $0.6M XXX XXX XXX XXX
S&M Expenses to Revenue 266% XXX XXX XXX XXX
G&A Expenses to Revenue 400% XXX XXX XXX XXX
R&D Expenses to Revenue 430% XXX XXX XXX XXX
Opex to Revenue 1082% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Mesoblast Public Comps

See public comps and valuation multiples for Regenerative Medicine and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Lineage Cell Therapeutics XXX XXX XXX XXX XXX XXX
Arovella Therapeutics XXX XXX XXX XXX XXX XXX
Aroa Biosurgery XXX XXX XXX XXX XXX XXX
Cynata Therapeutics XXX XXX XXX XXX XXX XXX
Orthocell XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Mesoblast M&A and Investment Activity

Mesoblast acquired  XXX companies to date.

Last acquisition by Mesoblast was  XXXXXXXX, XXXXX XXXXX XXXXXX . Mesoblast acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Mesoblast

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Mesoblast

When was Mesoblast founded? Mesoblast was founded in 2004.
Where is Mesoblast headquartered? Mesoblast is headquartered in Australia.
How many employees does Mesoblast have? As of today, Mesoblast has 73 employees.
Who is the CEO of Mesoblast? Mesoblast's CEO is Dr. Silviu Itescu, F.A.C.P.,F.R.A.C.P..
Is Mesoblast publicy listed? Yes, Mesoblast is a public company listed on ASX.
What is the stock symbol of Mesoblast? Mesoblast trades under MSB ticker.
When did Mesoblast go public? Mesoblast went public in 2004.
Who are competitors of Mesoblast? Similar companies to Mesoblast include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics.
What is the current market cap of Mesoblast? Mesoblast's current market cap is $1.7B
What is the current revenue of Mesoblast? Mesoblast's last 12-month revenue is $25.4M.
What is the current EBITDA of Mesoblast? Mesoblast's last 12-month EBITDA is -$71.7M.
What is the current EV/Revenue multiple of Mesoblast? Current revenue multiple of Mesoblast is 109.0x.
What is the current EV/EBITDA multiple of Mesoblast? Current EBITDA multiple of Mesoblast is -38.6x.
What is the current revenue growth of Mesoblast? Mesoblast revenue growth between 2023 and 2024 was -21%.
Is Mesoblast profitable? Yes, Mesoblast is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.